Amann Berthold, Luedemann Claas, Ratei Richard, Schmidt-Lucke J André
Department of Medicine, Franziskuskrankenhaus, Berlin Vascular Center, Berlin, Germany.
Cell Transplant. 2009;18(3):371-80. doi: 10.3727/096368909788534942. Epub 2009 Apr 2.
Bone marrow cell transplantation has been shown to induce angiogenesis and thus improve ischemic artery disease. This study evaluates the effects of intramuscular bone marrow cell transplantation in patients with limb-threatening critical limb ischemia with a very high risk for major amputation. After failed or impossible operative and/or interventional revascularization and after unsuccessful maximum conservative therapy, 51 patients with impending major amputation due to severe critical limb ischemia had autologous bone marrow cells (BMC) transplanted into the ischemic leg. Patients 1-12 received Ficoll-isolated bone marrow mononuclear cells (total cell number 1.1 +/- 1.1 x 10(9)), patients 13-51 received point of care isolated bone marrow total nucleated cells (3.0 +/- 1.7 x 10(9)). Limb salvage was 59% at 6 months and 53% at last follow-up (mean 411 +/- 261 days, range 175-1186). Perfusion measured with ankle-brachial index (ABI) and transcutaneous oxygen tension (tcpO(2)) at baseline and after 6 months increased in patients with consecutive limb salvage (ABI 0.33 +/- 0.18 to 0.46 +/- 0.15, tcpO(2) 12 +/- 12 to 25 +/- 15 mmHg) and did not change in patients eventually undergoing major amputation. No difference in clinical outcome between the isolation methods were seen. Clinically most important, patients with limb salvage improved from a mean Rutherford category of 4.9 at baseline to 3.3 at 6 months (p = 0.0001). Analgesics consumption was reduced by 62%. Total walking distance improved in nonamputees from zero to 40 m. Three severe periprocedural adverse events resolved without sequelae, and no unexpected long-term adverse events occurred. In no-option patients with end-stage critical limb ischemia due to peripheral artery disease, bone marrow cell transplantation is a safe procedure that can improve leg perfusion sufficiently to reduce major amputations and permit durable limb salvage.
骨髓细胞移植已被证明可诱导血管生成,从而改善缺血性动脉疾病。本研究评估了肌肉内骨髓细胞移植对有极高大截肢风险的威胁肢体的严重肢体缺血患者的影响。在手术和/或介入性血管重建失败或无法进行,以及最大程度的保守治疗未成功后,51例因严重肢体缺血即将面临大截肢的患者将自体骨髓细胞(BMC)移植到缺血的腿部。1至12号患者接受了经Ficoll分离的骨髓单个核细胞(细胞总数为1.1±1.1×10⁹),13至51号患者接受了床旁分离的骨髓有核细胞总数(3.0±1.7×10⁹)。6个月时肢体挽救率为59%,末次随访时为53%(平均411±261天,范围175 - 1186天)。连续肢体挽救的患者在基线和6个月后用踝臂指数(ABI)和经皮氧分压(tcpO₂)测量的灌注增加(ABI从0.33±0.18增至0.46±0.15,tcpO₂从12±12增至25±15 mmHg),最终接受大截肢的患者则无变化。两种分离方法的临床结局无差异。临床上最重要的是,肢体挽救的患者从基线时平均卢瑟福分级4.9改善至6个月时的3.3(p = 0.0001)。镇痛药消耗量减少了62%。非截肢患者的总步行距离从零增加到40米。3例严重的围手术期不良事件未遗留后遗症而得到解决,且未发生意外的长期不良事件。对于因外周动脉疾病导致的终末期严重肢体缺血的无其他选择的患者,骨髓细胞移植是一种安全的手术,可充分改善腿部灌注,以减少大截肢并实现持久的肢体挽救。